Skip to Main Content
Contribute Try STAT+ Today

As Tedros Adhanom Ghebreyesus of Ethiopia takes the helm of the World Health Organization this week as its eighth Director-General, and the first from sub-Saharan Africa, he has set an ambitious agenda for the organization. During his campaign for the office and since his election, Tedros has consistently emphasized WHO’s important role as a guardian of equity — in particular ensuring that the world’s poorest populations have access to health care as a fundamental human right.

As practitioners and advocates for improving the health of the world’s poorest and most vulnerable people, we applaud Tedros and WHO for their commitment to assuring universal health coverage for all. At the same time, we want to call his attention to a critical gap in the global agenda for health equity and universal health coverage — the crushing but largely overlooked burden of noncommunicable diseases and injuries on the world’s poorest people and communities.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.